NASDAQ:BIIB - Biogen Stock Price, News, & Analysis

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen Inc (NASDAQ:BIIB) released its earnings results on Tuesday, January, 29th. The biotechnology company reported $6.99 earnings per share for the quarter, beating analysts' consensus estimates of $6.72 by $0.27. The biotechnology company had revenue of $3.53 billion for the quarter, compared to analysts' expectations of $3.39 billion. Biogen had a net margin of 32.94% and a return on equity of 40.53%. Biogen's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.26 EPS. View Biogen's Earnings History.

Biogen is scheduled to release their next quarterly earnings announcement on Wednesday, April 24th 2019. View Earnings Estimates for Biogen.

Biogen will be holding an earnings conference call on Wednesday, April 24th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Biogen issued an update on its FY19 earnings guidance on Tuesday, January, 29th. The company provided EPS guidance of $28-29 for the period, compared to the Thomson Reuters consensus EPS estimate of $27.98. The company issued revenue guidance of $13.6-13.8 billion, compared to the consensus revenue estimate of $13.63 billion.Biogen also updated its FY 2019 guidance to $28.00-29.00 EPS.

30 brokerages have issued twelve-month price targets for Biogen's shares. Their forecasts range from $210.00 to $400.00. On average, they anticipate Biogen's share price to reach $295.0442 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price. View Analyst Price Targets for Biogen.

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 1 sell rating, 22 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.

Media coverage about BIIB stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biogen earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN) and Denali Therapeutics (DNLI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Allergan (AGN), Micron Technology (MU) and Intel (INTC).

Biogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Waverton Investment Management Ltd (0.15%), Retirement Systems of Alabama (0.08%), Saratoga Research & Investment Management (0.08%), DNB Asset Management AS (0.07%), Gateway Investment Advisers LLC (0.06%) and Country Trust Bank (0.06%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., Oakbrook Investments LLC, Calamos Advisors LLC, Strs Ohio, First Hawaiian Bank, Country Trust Bank, Waverton Investment Management Ltd and Trust Department MB Financial Bank N A. Company insiders that have sold Biogen company stock in the last year include Michael D Ehlers and Robert W Pangia. View Insider Buying and Selling for Biogen.

BIIB stock was purchased by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Virtu Financial LLC, DNB Asset Management AS, Pacer Advisors Inc., Saratoga Research & Investment Management, Hexavest Inc., Carnick & Kubik Group LLC and Ingalls & Snyder LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $229.12.

Biogen has a market capitalization of $45.07 billion and generates $13.45 billion in revenue each year. The biotechnology company earns $4.43 billion in net income (profit) each year or $26.20 on an earnings per share basis. Biogen employs 7,800 workers across the globe.

The official website for Biogen is http://www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]